Sisi Zhen1, Hui Wang1,2, Sizhou Feng3. 1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, 300020, China. 2. Department of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, Shandong Province, China. 3. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, 300020, China. szfeng@ihcams.ac.cn.
Abstract
PURPOSE: Multidrug-resistant Gram-negative bacteria (MDR-GNB) have become a major global public health threat. Ceftazidime-avibactam (CAZ-AVI) is a newer combination of β-lactam/β-lactamase inhibitor, with activity against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA). The aim of this review is to describe the recent real-world experience of CAZ-AVI for the infections due to MDR-GNB. METHODS: We searched PubMed, Embase and Google Scholar for clinical application in CAZ-AVI for MDR-GNB infections. Reference lists were reviewed and synthesized for narrative review. RESULTS: MDRGNB infections are associated with higher mortality significantly comparing to drug-susceptible bacterial infections. Fortunately, CAZ-AVI shows significant benefits for infections due to KPC or OXA-48 CRE, comparing to colistin, carbapenem, aminoglycoside and other older agents, even in those with immunocompromised status. The efficacy of CAZ-AVI varies in different infection sites due to CRE, which is lower in pneumonia. Early use is associated with improved clinical outcomes. Noteworthy, when adopted as salvage therapy, CAZ-AVI is still superior to other GNB active antibiotics. CAZ-AVI plus aztreonam is recommended as the first line of MBL-CRE infections. However, for infections caused by KPC- and OXA-48-producing isolates, further investigations are needed to demonstrate the benefit of combination therapy. Besides CRE, CAZ-AVI is also active to MDR-PA. However, the development of resistance in CRE and MDR-PA against CAZ-AVI is alarming, and more investigations and studies are needed to prevent, diagnose, and treat infections due to CAZ-AVI-resistant pathogens. CONCLUSIONS: CAZ-AVI appears to be a valuable therapeutic option in MDR-GNB infections. Using CAZ-AVI appropriately to improve efficacy and decrease the emergence of resistance is important.
PURPOSE: Multidrug-resistant Gram-negative bacteria (MDR-GNB) have become a major global public health threat. Ceftazidime-avibactam (CAZ-AVI) is a newer combination of β-lactam/β-lactamase inhibitor, with activity against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA). The aim of this review is to describe the recent real-world experience of CAZ-AVI for the infections due to MDR-GNB. METHODS: We searched PubMed, Embase and Google Scholar for clinical application in CAZ-AVI for MDR-GNB infections. Reference lists were reviewed and synthesized for narrative review. RESULTS: MDRGNB infections are associated with higher mortality significantly comparing to drug-susceptible bacterial infections. Fortunately, CAZ-AVI shows significant benefits for infections due to KPC or OXA-48 CRE, comparing to colistin, carbapenem, aminoglycoside and other older agents, even in those with immunocompromised status. The efficacy of CAZ-AVI varies in different infection sites due to CRE, which is lower in pneumonia. Early use is associated with improved clinical outcomes. Noteworthy, when adopted as salvage therapy, CAZ-AVI is still superior to other GNB active antibiotics. CAZ-AVI plus aztreonam is recommended as the first line of MBL-CRE infections. However, for infections caused by KPC- and OXA-48-producing isolates, further investigations are needed to demonstrate the benefit of combination therapy. Besides CRE, CAZ-AVI is also active to MDR-PA. However, the development of resistance in CRE and MDR-PA against CAZ-AVI is alarming, and more investigations and studies are needed to prevent, diagnose, and treat infections due to CAZ-AVI-resistant pathogens. CONCLUSIONS: CAZ-AVI appears to be a valuable therapeutic option in MDR-GNB infections. Using CAZ-AVI appropriately to improve efficacy and decrease the emergence of resistance is important.
Authors: Hajo Grundmann; Corinna Glasner; Barbara Albiger; David M Aanensen; Chris T Tomlinson; Arjana Tambić Andrasević; Rafael Cantón; Yehuda Carmeli; Alexander W Friedrich; Christian G Giske; Youri Glupczynski; Marek Gniadkowski; David M Livermore; Patrice Nordmann; Laurent Poirel; Gian M Rossolini; Harald Seifert; Alkiviadis Vatopoulos; Timothy Walsh; Neil Woodford; Dominique L Monnet Journal: Lancet Infect Dis Date: 2016-11-18 Impact factor: 25.071
Authors: Lindsey M Weiner; Amy K Webb; Brandi Limbago; Margaret A Dudeck; Jean Patel; Alexander J Kallen; Jonathan R Edwards; Dawn M Sievert Journal: Infect Control Hosp Epidemiol Date: 2016-08-30 Impact factor: 3.254
Authors: Maria Virginia Villegas; Christian J Pallares; Kevin Escandón-Vargas; Cristhian Hernández-Gómez; Adriana Correa; Carlos Álvarez; Fernando Rosso; Lorena Matta; Carlos Luna; Jeannete Zurita; Carlos Mejía-Villatoro; Eduardo Rodríguez-Noriega; Carlos Seas; Manuel Cortesía; Alfonso Guzmán-Suárez; Manuel Guzmán-Blanco Journal: PLoS One Date: 2016-04-22 Impact factor: 3.240
Authors: Carolina Garcia-Vidal; Celia Cardozo-Espinola; Pedro Puerta-Alcalde; Francesc Marco; Adrian Tellez; Daiana Agüero; Francisco Romero-Santana; Marina Díaz-Beyá; Eva Giné; Laura Morata; Olga Rodríguez-Núñez; Jose Antonio Martinez; Josep Mensa; Jordi Esteve; Alex Soriano Journal: PLoS One Date: 2018-06-28 Impact factor: 3.240
Authors: Dee Shortridge; Ana C Gales; Jennifer M Streit; Michael D Huband; Athanasios Tsakris; Ronald N Jones Journal: Open Forum Infect Dis Date: 2019-03-15 Impact factor: 3.835